KeyBanc lowered the firm’s price target on Stevanato Group (STVN) to $32 from $37 and keeps an Overweight rating on the shares. The firm notes the company’s Q4 print was a top- to bottom-line beat and FY25 performance was driven by 50% year-over-year GLP-1 revenue growth to 19% of revenue. However, mid-teens FY26 GLP-1 guide shifts the emphasis to the core biologic business, KeyBanc adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STVN:
- Stevanato Group price target lowered to $26 from $32 at Citi
- Stevanato: GLP-1-Driven Strength Offset by Engineering Weakness Keeps Risk-Reward Balanced at Hold
- Stevanato Group Posts Record High‑Value Revenue and Strong 2025 Results, Sets Upbeat 2026 Outlook
- Stevanato Group Files Form 6-K With Q4 and FY 2025 Results Presentation
- Stevanato Group price target lowered to $28 from $30 at BofA